MYTIRAZ

Glaxo Group Limited

Application Filed: 2012-09-14

Trademark Application Details

Status

604

Dead/Abandoned

ABANDONED - AFTER INTER-PARTES DECISION

Research	OneLook Acronym Finder
Serial Number	85729516
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Christopher M. Hanes
Attorney Docket Number	TMR\5086040\
Law Office Assigned	M30
Employee Name	GARDNER, DAWNA BERYL

Timeline

2012-09-14	Application Filed
2013-02-26	Published for Opposition
2013-10-10	Abandon
2013-10-10	Location: TTAB
2013-10-10	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	Glaxo Group Limited
Address	980 Great West Road Brentford, Middles GB TW89GS
Legal Entity Type	Corporation
Legal Entity State	GB

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

CHRISTOPHER M. HANES
GLAXOSMITHKLINE
5 MOORE DR
RESEARCH TRIANGLE PARK, NC 27709-0183

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(e)) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Type Code

Type

GS0051

(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(e)) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2012-09-18	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2012-09-20	2 NWOS I:Incoming Correspondence
NOTICE OF PSEUDO MARK MAILED	2012-09-21	3 MPMK O:Outgoing Correspondence
ASSIGNED TO EXAMINER	2013-01-07	4 DOCK D:Assigned to Examiner
APPROVED FOR PUB - PRINCIPAL REGISTER	2013-01-09	5 CNSA P:
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED	2013-01-18	6 ERRR O:Outgoing Correspondence
ELECTRONIC RECORD REVIEW COMPLETE	2013-01-22	7 FIXD O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2013-02-06	8 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2013-02-26	9 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2013-02-26	10 NPUB E:E-Mail
TEAS CHANGE OF OWNER ADDRESS RECEIVED	2013-03-25	11 COAR I:Incoming Correspondence
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED	2013-03-25	12 CHAN I:Incoming Correspondence
EXTENSION OF TIME TO OPPOSE RECEIVED	2013-03-28	13 ETOF T:TTAB Proceeding
OPPOSITION INSTITUTED NO. 999999	2013-06-25	14 OP.I T:TTAB Proceeding
OPPOSITION DISMISSED NO. 999999	2013-10-10	15 OP.D T:TTAB Proceeding
OPPOSITION TERMINATED NO. 999999	2013-10-10	16 OP.T T:TTAB Proceeding
ABANDONMENT - AFTER INTER PARTES DECISION	2013-10-10	17 ABN4 O:Outgoing Correspondence
ABANDONMENT NOTICE MAILED - INTER PARTES DECISION	2013-10-10	18 MAB4 O:Outgoing Correspondence

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.